561.88MMarket Cap-5.03P/E (TTM)
8.580High7.705Low4.74MVolume8.380Open8.400Pre Close38.57MTurnover6.71%Turnover RatioLossP/E (Static)71.12MShares14.84052wk High4.21P/B557.72MFloat Cap5.27552wk Low--Dividend TTM70.60MShs Float978.000Historical High--Div YieldTTM10.42%Amplitude-1731.000Historical Low8.137Avg Price1Lot Size
Altimmune Stock Forum
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet